Ricoh buys Lanier, voice line goes to Platinum
Ricoh and Lanier Worldwide have signed a definitive merger agreement, unanimously approved by Lanier's board, under which Ricoh will make a cash tender offer of $3 per share for all outstanding shares of Lanier common stock. However, Lanier's
Ricoh and Lanier Worldwide have signed a definitive merger agreement, unanimously approved by Lanier's board, under which Ricoh will make a cash tender offer of $3 per share for all outstanding shares of Lanier common stock. However, Lanier's voice products are not directly part of the deal. The merger with Ricoh is subject to regulatory approval and contingent on the sale of Lanier's voice business to Platinum Equity Holdings, a privately held firm specializing in acquiring and operating high-tech firms. The new voice products company, to be known as Lanier Health Care, has approximately 500 employees. Lanier should complete the transfer of its voice business within 30 days. Platinum projects sales in excess of $120 million for the 2001 fiscal year for Lanier Health Care.
© 2000 Miller Freeman Inc.
12/13/00, Issue # 118, page 3.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
